IPN60340 with two leukemia drugs for newly diagnosed blood cancer
Part of Blood & lymphatic, Cancer clinical trials.
This study tests whether adding a new medicine called IPN60340 to two standard leukemia treatments (azacitidine and venetoclax) works better than those two treatments alone. It's for people newly diagnosed with acute myeloid leukemia who cannot tolerate aggressive chemotherapy due to age or other health conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Newly diagnosed acute myeloid leukemia (AML) confirmed by recent testing
- Not eligible for intensive chemotherapy because of age, frailty, or serious health problems
- Adequate organ function (kidneys, liver, heart working well enough)
- No prior treatment with similar leukemia drugs or chemotherapy
- Able to swallow pills and willing to use birth control during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (an IDO1 inhibitor and a PD-1 blocker) given with standard chemotherapy (azacitidine and venetoclax) for people newly diagnosed with acute myeloid leukemia (AML) who cannot have intensive chemotherapy. The goal is to see if this approach helps the immune system fight the leukemia better.
This study tests a new three-drug combination (pivekimab sunirine, venetoclax, and azacitidine) for newly diagnosed acute myeloid leukemia in patients who cannot tolerate intensive chemotherapy. The goal is to see if this combination is safe and effective at controlling the disease.
This trial tests a new drug combination (bleximenib, venetoclax, and azacitidine) for people with a specific genetic type of AML who cannot receive strong chemotherapy. The goal is to see if this combination is safer and more effective.
This trial tests a new drug, MAX-40279, combined with two standard treatments (venetoclax and azacitidine) for people with newly diagnosed acute myeloid leukemia who are not healthy enough for intensive chemotherapy. The goal is to see if adding this drug improves outcomes.
This trial tests a new drug called AK117 combined with two standard AML medicines (azacitidine and venetoclax) for people with acute myeloid leukemia who haven't had certain prior treatments. The goal is to see if this combination works better and is safe.
This trial tests a new drug, JNJ-90189892, for people with certain types of blood cancers (acute myeloid leukemia or higher-risk myelodysplastic neoplasms) that have come back or not responded to treatment. The goal is to see if the drug is safe and effective.
Hear when a new Acute Myeloid Leukaemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.